Theramex Entered into an Agreement with Enzene Biosciences to Develop and Commercialize Tocilizumab Biosimilar for Rheumatoid Arthritis
Shots:
- The companies collaborated to develop, and commercialize a biosimilar of Roche’s RoActemra (Tocilizumab)
- Tocilizumab + MTX is indicated for the treatment of RA & plans to commercialize the product from 2026 in the EU, UK, Switzerland, and Australia
- Theramex’s Tocilizumab product will be available in parenteral vials, SC PFS & autoinjectors. RoActemra is indicated for the treatment of RA, systemic JIA in patients aged ≥1yr., juvenile idiopathic polyarthritis in patients aged 2 yr. & giant cell arteritis
Ref: Businesswire | Image: Theramex
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
